Nanoviricides are currently binary: they either work in humans as they have in animals, or they don't. IMO, there is nothing in between. If they work in humans, then $10 billion will be leaving $40 billion on the table. Pharmassette went for $11 billion with one drug completing Phase 2 and ready for Phase 3. Do the math with that and 5 antiviral drugs plus 200 more in development.
that would be a low-ball valuation on a successful flu drug alone (that's using a figure of about $2B in annual sales, which could be conservative.... company estimates have been $4-$7B in annual sales for a successful flu drug).
News 
Market Data 
Discover 
